Navigation Links
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
Date:4/3/2012

ring from osteoporosis, there is a serious patient need for therapeutics that help build bone.  Amgen and UCB are collaborating on the development of CDP7851/AMG 785 for the treatment of bone-related conditions, including postmenopausal osteoporosis and fracture healing.

About Postmenopausal Osteoporosis

Osteoporosis is the most common disorder of bone metabolism. Osteoporosis, or porous bone, is a chronic, progressive and systemic disease marked by low bone mass, deterioration of bone tissue and low bone strength, leading to bone fragility and an increased risk of fractures. The rate of bone loss is accelerated in women during and after the menopause as a result of estrogen deficiency associated with the loss of ovarian function at menopause. The risk of fracture increases exponentially with age. The prevalence of osteoporosis is estimated to be 64.6 million people in the seven major markets; women are four times more likely than men to develop osteoporosis.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

UCB Forward-looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By th
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... addition of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses ... in the United States . Reimbursement ... studied. Thorough product analyses for more than 73 SMBG ...
(Date:12/22/2014)... Dec. 22, 2014 Cyberonics, Inc. (NASDAQ: ... treatment and management of epilepsy, today announced it will participate ... on Wednesday, January 14, 2015, in San Francisco ... and Chief Executive Officer, will speak at 11:00 AM Pacific ... accessed by clicking on the Investor Relations link on the ...
(Date:12/22/2014)... ALTO, Calif. , Dec, 22, 2014 /PRNewswire/ ... a Phase 2a study of lonafarnib in patients ... study was conducted at the National Institutes of ... Maryland .  The double-blinded, randomized, placebo-controlled, dose ... mg twice daily and 200 mg twice daily ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Amgen (NASDAQ: AMGN ) today announced positive ... study of the pivotal Phase 3 fracture trial showing that ... osteoporosis was associated with continued increase in bone mineral density ... results will be presented on Nov. 8, 2011, at the ...
... Nov. 5, 2011 Supported by a patient-safety ... Radiologic Technology Week® kicks off Nov. 6. ... the theme for this year,s NRTW, Nov. 6-12. Selected by ... group of practicing R.T.s, it promotes a fundamental principle of ...
Cached Medicine Technology:Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 2Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 3Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 4Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 5Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 6Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 7Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 8Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 9Passion for Patient Care Marks 2011 National Radiologic Technology Week® 2
(Date:12/25/2014)... (PRWEB) December 25, 2014 Thousands of ... move forward in a number of multidistrict litigations currently ... Virginia, Bernstein Liebhard LLP reports. According to an Order ... to convene a Joint Status Conference in all of ... Parties have been directed to submit a proposed agenda ...
(Date:12/25/2014)... Residents at Abernethy Laurels ... their generous spirit by providing holiday gifts to ... Network- Grandparents Raising Grandchildren program. , Following a ... largest Christmas tree on the campus of the ... of the Abernethy Village Association (AVA). Each holiday ...
(Date:12/24/2014)... 25, 2014 AlignLife of Wauwatosa ... afford certain items. During the holiday season, AlignLife looks forward ... 70 toys," says Dr. Sara Mahalko-Leonhardt, owner of AlignLife. "It ... joy, knowing that we are able to give kids toys ... not been for the generosity of our patients." , The ...
(Date:12/24/2014)... 24, 2014 Connie Casad, MD, a ... medicine advocate with 30 years of practice experience in ... the health benefits of dietary detoxification. The second study ... following excellent results from test patients who just completed ... explain her interest in conducting the study, Dr. Casad ...
(Date:12/24/2014)... New studies reveal that women under the age ... (March 6, 2014, JAMA Otolaryngology*). And although many people choose ... percent according to recent polls) facing hearing loss head on ... feels and relates to the world. People who have benefited ... by way of:, , self-confidence , ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6
... Now Have Access to Advanced Medical Expertise When Faced ... Nippon Life Benefits, a leading provider of employee ... members will have access to Best Doctors, an expert ... are getting the right diagnosis and treatment. The new ...
... COLUMBIA, S.C., Jan. 12 Medical travel company ... and individuals access lower-cost health care at accredited ... for providing useful information and outstanding customer service ... .The Columbia-based company received second-place honors in the ...
... cell findings could reveal targets for future treatments , , ... have discovered genes in prostate cancer cells that fuse ... occurrence that may initiate the development of some cancers. ... of Michigan Comprehensive Cancer Center, appear only in cancer ...
... 12 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... of medical devices worldwide, today announced selected preliminary,unaudited ... 2008. The,preliminary results reported below include the ... from Datascope ("DPM") starting from May,1, 2008. , ...
... 12 , - Small ... , With the introduction of ... messaging device, NEC sets new standards in,mobile communications and ... innovations. , (Photo: http://www.newscom.com/cgi-bin/prnh/20090112/333834 ...
... Reuters today announced that it has published a new ... expert insight from academics and key players in the ... the Drug Development Toolkit," it explores the role of ... challenges seen in clinical research and their potential ...
Cached Medicine News:Health News:Nippon Life Benefits Partners with Best Doctors to Help Members Make More Informed Health Care Decisions 2Health News:Nippon Life Benefits Partners with Best Doctors to Help Members Make More Informed Health Care Decisions 3Health News:Companion Global Healthcare Awarded for Outstanding Web Site 2Health News:Mindray Announces Preliminary 2008 Operating Results 2Health News:Mindray Announces Preliminary 2008 Operating Results 3Health News:Mindray Announces Preliminary 2008 Operating Results 4Health News:NEC's new M155 Messenger Sets New Standards in Mobile Messaging 2Health News:Thomson Reuters White Paper Explores the Role of Biomarkers in Clinical Trials and Drug Development 2Health News:Thomson Reuters White Paper Explores the Role of Biomarkers in Clinical Trials and Drug Development 3
...
Angled 45 Degrees to Right, 9.5mm blade, gently curved .5x .25mm blunt tips; Lower blade is 0.5mm longer; 14mm from mid screw to tip; (Available in left and right;) overall length 120mm; Stainless ...
16mm Slightly Curved sharp Tips; overall length 120mm; Stainless Steel...
16mm from Mid-Screw to Blunt Tips, Gently Curved Blades; overall length 120mm; Stainless Steel...
Medicine Products: